Please assess the completion status of the following clinical trial:

Trial Title: Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she is using an acceptable method of birth control.~* 18 years or older~* Patient must have pain associated with cancer or cancer treatment.~* Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000 mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30 mg, methadone 20 mg, and hydromorphone 7.5 mg).~* Regularly experiences 1 - 4 breakthrough pain episodes per day that require additional opioids for pain control~* At least partial relief of breakthrough pain by use of opioid therapy~* Subject must be able to self-administer the study medication correctly.~* Subject must be willing and able to complete the electronic diary card with each pain episode.~* Signed consent must be obtained at screening prior to any procedures being performed.~Exclusion Criteria:~* Psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary~* Cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression~* Recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse~* Rapidly escalating pain that the investigator believes may require an increase in the dosage of background pain medication during the study~* Moderate (Grade 3) to severe (Grade 4) mucositis (Subjects with less than moderate mucositis are permitted and must be instructed to not apply the BEMA disc at a site of inflammation.)~* Strontium 89 therapy within the previous 6 months~* Any other therapy prior to the study that the investigator considers could alter pain or the response to pain medication.~* Use of an investigational drug within 4 weeks preceding this study~* History of hypersensitivity or intolerance to fentanyl~* Regularly more than 4 episodes per day~* Eastern Cooperative Oncology Group (ECOG) performance status of 4 or 5~* Subject is pregnant, actively trying to become pregnant, breast feeding or not using adequate contraceptive measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- BEMA™ Fentanyl (Type: EXPERIMENTAL): BioErodible MucoAdhesive (BEMA) Fentanyl

Based on this trial design, predict the completion outcome and termination type (if applicable).